Castle Biosciences Inc (CSTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2025 | 12-2024 | 09-2024 | 06-2024 | 03-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 89,689 | 119,709 | 94,959 | 85,572 | 82,949 |
| Marketable Securities | 185,462 | 173,421 | 184,826 | 174,116 | 156,264 |
| Receivables | 56,353 | 51,218 | 50,261 | 45,988 | 42,699 |
| Inventories | 6,849 | 8,135 | 6,572 | 8,013 | 7,645 |
| TOTAL | $349,388 | $360,154 | $344,772 | $320,405 | $295,778 |
| Non-Current Assets | |||||
| PPE Net | 55,423 | 51,122 | 44,383 | 38,638 | 32,904 |
| Investments And Advances | 5,570 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 91,334 | 119,959 | 125,410 | 128,269 | 129,825 |
| TOTAL | $152,327 | $171,081 | $169,793 | $166,907 | $162,729 |
| Total Assets | $501,715 | $531,235 | $514,565 | $487,312 | $458,507 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,111 | 278 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 8,502 | 6,901 | 6,810 | 9,540 | 9,318 |
| Accrued Expenses | 17,857 | 32,555 | 27,672 | 21,239 | 14,708 |
| TOTAL | $37,274 | $49,392 | $44,295 | $39,454 | $31,959 |
| Non-Current Liabilities | |||||
| Long Term Debt | 8,921 | 9,745 | 10,015 | 10,008 | 10,000 |
| Other Non-Current Liabilities | 14,049 | 14,345 | 14,691 | 13,645 | 13,880 |
| TOTAL | $24,135 | $26,008 | $29,215 | $23,965 | $24,086 |
| Total Liabilities | $61,409 | $75,400 | $73,510 | $63,419 | $56,045 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 28,872 | 28,514 | 28,007 | 27,737 | 27,607 |
| Common Shares | 29 | 28 | 28 | 28 | 28 |
| Retained earnings | -225,974 | -200,126 | -209,716 | -211,985 | -220,905 |
| Other shareholders' equity | 131 | 230 | 473 | -172 | -111 |
| TOTAL | $440,306 | $455,835 | $441,055 | $423,893 | $402,462 |
| Total Liabilities And Equity | $501,715 | $531,235 | $514,565 | $487,312 | $458,507 |